BeStock  
Stocks › Biotechnology › AKTS

Aktis Oncology AKTS

US equityMarket cap rank #3226Biotechnology
$16.15 −$0.25 (-1.52%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $16.46 +1.92%
Open$16.32
Prev close$16.40
Day range$16.00 – $16.74
Volume375.0K
Market cap$901.14M
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-10.6x
CheapRich

Near the top of its 5-year range · 99th percentile, 5-year average -16.6x

Price / book2.0x
CheapRich

Around its usual level · 52nd percentile, 5-year average -1.5x

#3100 of 5329 stocks by PB (1 = cheapest)

Price / sales74.9x
CheapRich

Near the bottom of its 5-year range · 2nd percentile, 5-year average 148.4x

#4914 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-29x-18x-8x2xJan '26Jun '26Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$20.02
Price vs. fair value-19.3%Trading below the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 2.02 – -1.47 52% (pricier than usual) #3100 of 5329 (1 = cheapest)
PE -10.59 -6.36 -16.64 99% (pricier than usual) –
PS 74.87 88.21 148.39 2% (cheaper than usual) #4914 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on AKTS.

Sign in to join the discussion.

Scroll to Top